Literature DB >> 29399441

NK Cells and γδT Cells for Relapse Protection After Allogeneic Hematopoietic Cell Transplantation (HCT).

Moniek A de Witte1,2, Jürgen Kuball2,3, Jeffrey S Miller1.   

Abstract

PURPOSE OF REVIEW: The outcome of allogeneic stem cell transplantation (allo-HCT) is still compromised by relapse and complications. NK cells and γδT cells, effectors which both function through MHC-unrestricted mechanisms, can target transformed and infected cells without inducing Graft-versus-Host Disease (GVHD). Allo-HCT platforms based on CD34+ selection or αβ-TCR depletion result in low grades of GVHD, early immune reconstitution (IR) of NK and γδT cells and minimal usage of GVHD prophylaxis. In this review we will discuss strategies to retain and expand the quantity, diversity and functionality of these reconstituting innate cell types. RECENT
FINDINGS: Bisphosphonates, IL-15 cytokine administration, specific antibodies, checkpoint inhibitors and (CMV based) vaccination are currently being evaluated to enhance IR. All these approaches have shown to potentially enhance both NK and γδT cell immuno-repertoires.
SUMMARY: Rapidly accumulating data linking innate biology to proposed clinical immune interventions, will give unique opportunities to unravel shared pathways which determine the Graft-versus-Tumor effects of NK and γδT cells.

Entities:  

Keywords:  NK cells; allogeneic stem cell transplantation; immune reconstitution; γδT cells

Year:  2017        PMID: 29399441      PMCID: PMC5791765          DOI: 10.1007/s40778-017-0106-4

Source DB:  PubMed          Journal:  Curr Stem Cell Rep


  108 in total

1.  Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab.

Authors:  Kilian Wistuba-Hamprecht; Alexander Martens; Karin Haehnel; Marnix Geukes Foppen; Jianda Yuan; Michael A Postow; Phillip Wong; Emanuela Romano; Amir Khammari; Brigitte Dreno; Mariaelena Capone; Paolo A Ascierto; Ilja Demuth; Elisabeth Steinhagen-Thiessen; Anis Larbi; Bastian Schilling; Dirk Schadendorf; Jedd D Wolchok; Christian U Blank; Graham Pawelec; Claus Garbe; Benjamin Weide
Journal:  Eur J Cancer       Date:  2016-07-09       Impact factor: 9.162

Review 2.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

3.  Reconstitution of gammadelta T cell repertoire diversity after human allogeneic hematopoietic cell transplantation and the role of peripheral expansion of mature T cell population in the graft.

Authors:  M Hirokawa; T Horiuchi; Y Kawabata; A Kitabayashi; A B Miura
Journal:  Bone Marrow Transplant       Date:  2000-07       Impact factor: 5.483

4.  Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset.

Authors:  Christelle Harly; Yves Guillaume; Steven Nedellec; Cassie-Marie Peigné; Hannu Mönkkönen; Jukka Mönkkönen; Jianqiang Li; Jürgen Kuball; Erin J Adams; Sonia Netzer; Julie Déchanet-Merville; Alexandra Léger; Thomas Herrmann; Richard Breathnach; Daniel Olive; Marc Bonneville; Emmanuel Scotet
Journal:  Blood       Date:  2012-07-05       Impact factor: 22.113

5.  Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients.

Authors:  Ahmet H Elmaagacli; Nina K Steckel; Michael Koldehoff; Yael Hegerfeldt; Rudolf Trenschel; Markus Ditschkowski; Sandra Christoph; Tanja Gromke; Lambros Kordelas; Hellmut D Ottinger; Rudolf S Ross; Peter A Horn; Susanne Schnittger; Dietrich W Beelen
Journal:  Blood       Date:  2011-05-03       Impact factor: 22.113

6.  High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.

Authors:  Leo Luznik; Javier Bolaños-Meade; Marianna Zahurak; Allen R Chen; B Douglas Smith; Robert Brodsky; Carol Ann Huff; Ivan Borrello; William Matsui; Jonathan D Powell; Yvette Kasamon; Steven N Goodman; Allan Hess; Hyam I Levitsky; Richard F Ambinder; Richard J Jones; Ephraim J Fuchs
Journal:  Blood       Date:  2010-02-02       Impact factor: 22.113

7.  IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells.

Authors:  Yumeng Mao; Vincent van Hoef; Xiaonan Zhang; Erik Wennerberg; Julie Lorent; Kristina Witt; Laia Masvidal; Shuo Liang; Shannon Murray; Ola Larsson; Rolf Kiessling; Andreas Lundqvist
Journal:  Blood       Date:  2016-07-27       Impact factor: 22.113

Review 8.  Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies.

Authors:  Michael Boeckh; W Garrett Nichols; Genovefa Papanicolaou; Robert Rubin; John R Wingard; John Zaia
Journal:  Biol Blood Marrow Transplant       Date:  2003-09       Impact factor: 5.742

9.  Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.

Authors:  S A Rosenberg; J C Yang; S L Topalian; D J Schwartzentruber; J S Weber; D R Parkinson; C A Seipp; J H Einhorn; D E White
Journal:  JAMA       Date:  1994 Mar 23-30       Impact factor: 56.272

Review 10.  Targeting natural killer cells in cancer immunotherapy.

Authors:  Camille Guillerey; Nicholas D Huntington; Mark J Smyth
Journal:  Nat Immunol       Date:  2016-08-19       Impact factor: 25.606

View more
  7 in total

1.  αβ T-cell graft depletion for allogeneic HSCT in adults with hematological malignancies.

Authors:  Moniek A de Witte; Anke Janssen; Klaartje Nijssen; Froso Karaiskaki; Luuk Swanenberg; Anna van Rhenen; Rick Admiraal; Lotte van der Wagen; Monique C Minnema; Eefke Petersen; Reinier A P Raymakers; Kasper Westinga; Trudy Straetemans; Constantijn J M Halkes; Jaap-Jan Boelens; Jürgen Kuball
Journal:  Blood Adv       Date:  2021-01-12

2.  Early Reconstitution of NK and γδ T Cells and Its Implication for the Design of Post-Transplant Immunotherapy.

Authors:  Moniek A de Witte; Dhifaf Sarhan; Zachary Davis; Martin Felices; Daniel A Vallera; Peter Hinderlie; Julie Curtsinger; Sarah Cooley; John Wagner; Jurgen Kuball; Jeffrey S Miller
Journal:  Biol Blood Marrow Transplant       Date:  2018-03-02       Impact factor: 5.742

3.  Granulocyte Colony-Stimulating Factor Effectively Mobilizes TCR γδ and NK Cells Providing an Allograft Potentially Enhanced for the Graft-Versus-Leukemia Effect for Allogeneic Stem Cell Transplantation.

Authors:  Lia Minculescu; Henrik Sengelov; Hanne Vibeke Marquart; Lars Peter Ryder; Anne Fischer-Nielsen; Eva Haastrup
Journal:  Front Immunol       Date:  2021-03-10       Impact factor: 7.561

4.  The EHA Research Roadmap: Immune-based Therapies for Hematological Malignancies.

Authors:  Hermann Einsele; Javier Briones; Fabio Ciceri; Irene García Cadenas; Fred Falkenburg; Natacha Bolaños; H M Mirjam Heemskerk; Roch Houot; Michael Hudecek; Franco Locatelli; Kate Morgan; Emma C Morris; Michael O'Dwyer; Jordi Gil Sierra; Marcel van den Brink; Arjan A van de Loosdrecht
Journal:  Hemasphere       Date:  2021-09-10

Review 5.  Allogeneic Stem Cell Transplantation Platforms With Ex Vivo and In Vivo Immune Manipulations: Count and Adjust.

Authors:  Moniek de Witte; Laura G M Daenen; Lotte van der Wagen; Anna van Rhenen; Reiner Raymakers; Kasper Westinga; Jürgen Kuball
Journal:  Hemasphere       Date:  2021-06-01

6.  Improved Overall Survival, Relapse-Free-Survival, and Less Graft-vs.-Host-Disease in Patients With High Immune Reconstitution of TCR Gamma Delta Cells 2 Months After Allogeneic Stem Cell Transplantation.

Authors:  Lia Minculescu; Hanne Vibeke Marquart; Lars Peter Ryder; Niels Smedegaard Andersen; Ida Schjoedt; Lone Smidstrup Friis; Brian Thomas Kornblit; Søren Lykke Petersen; Eva Haastrup; Anne Fischer-Nielsen; Joanne Reekie; Henrik Sengelov
Journal:  Front Immunol       Date:  2019-08-22       Impact factor: 7.561

7.  Genome editing of donor-derived T-cells to generate allogenic chimeric antigen receptor-modified T cells: Optimizing αβ T cell-depleted haploidentical hematopoietic stem cell transplantation.

Authors:  Volker Wiebking; Ciaran M Lee; Nathalie Mostrel; Premanjali Lahiri; Rasmus Bak; Gang Bao; Maria Grazia Roncarolo; Alice Bertaina; Matthew H Porteus
Journal:  Haematologica       Date:  2021-03-01       Impact factor: 9.941

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.